Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists

被引:52
作者
Novikoff, Aaron [1 ,2 ,3 ]
O'Brien, Shannon L. [4 ,5 ,6 ]
Bernecker, Miriam [1 ,2 ]
Grandl, Gerald [1 ,2 ]
Kleinert, Maximilian [1 ,2 ]
Knerr, Patrick J. [7 ]
Stemmer, Kerstin [1 ,2 ]
Klingenspor, Martin [8 ]
Zeigerer, Anja [2 ,9 ,10 ]
DiMarchi, Richard [11 ]
Tschoep, Matthias H. [2 ,3 ,12 ,13 ]
Finan, Brian [7 ]
Calebiro, Davide [4 ,5 ,6 ]
Mueller, Timo D. [1 ,2 ,14 ]
机构
[1] Helmholtz Zentrum Munchen, Inst Diabet & Obes, Helmholtz Diabet Ctr, Neuherberg, Germany
[2] German Ctr Diabet Res DZD, Neuherberg, Germany
[3] Tech Univ Munich, Dept Med, Div Metab Dis, D-80333 Munich, Germany
[4] Univ Birmingham, Inst Metab & Syst Res, Birmingham B15 2TT, W Midlands, England
[5] Univ Nottingham, Ctr Membrane Prot & Receptors COMPARE, Birmingham B15 2TT, W Midlands, England
[6] Univ Birmingham, Ctr Membrane Prot & Receptors COMPARE, Birmingham B15 2TT, W Midlands, England
[7] Novo Nordisk Res Ctr Indianapolis, Indianapolis, IN 46241 USA
[8] Tech Univ Munich, Sch Life Sci, Chair Mol Nutr Med, D-85354 Freising Weihenstephan, Germany
[9] Helmholtz Ctr Munich, Inst Diabet & Canc, D-85764 Neuherberg, Germany
[10] Univ Heidelberg Hosp, Inner Med 1, Joint Heidelberg IDC Translat Diabet Program, Heidelberg, Germany
[11] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA
[12] Helmholtz Zentrum Munchen, Neuherberg, Germany
[13] Tech Univ Munich, Munich, Germany
[14] Eberhard Karls Univ Hosp & Clin, Inst Expt & Clin Pharmacol & Toxicol, Dept Pharmacol & Expt Therapy, D-72076 Tubingen, Germany
来源
MOLECULAR METABOLISM | 2020年 / 49卷
基金
英国惠康基金; 欧洲研究理事会;
关键词
GLP-1R; GIPR; Biased agonism; Receptor Internalization; Receptor Trafficking; Dual-agonists; GLUCAGON-LIKE PEPTIDE-1; IN-VITRO; DEGRADATION; POLYPEPTIDE; MEMBRANE;
D O I
10.1016/j.molmet.2021.101181
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We assessed the spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics of GIPR mono-agonists, GLP-1R mono-agonists including semaglutide, and GLP-1/GIP dual-agonists MAR709 and tirzepatide. Methods: Receptor G protein recruitment and internalization/trafficking dynamics were assessed using bioluminescence resonance energy transfer (BRET)-based technology and live-cell HILO microscopy. Results: Relative to native and acylated GLP-1 agonists, MAR709 and tirzepatide showed preserved maximal cAMP production despite partial Gas recruitment paralleled by diminished ligand-induced receptor internalization at both target receptors. Despite MAR709's lower internalization rate, GLP-1R co-localization with Rab11-associated recycling endosomes was not different between MAR709 and GLP-1R specific monoagonists. Conclusions: Our data indicated that MAR709 and tirzepatide induce unique spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics relative to native peptides, semaglutide, and matched mono-agonist controls. These findings support the hypothesis that the structure of GLP-1/GIP dual-agonists confer a biased agonism that, in addition to its influence on intracellular signaling, uniquely modulates receptor trafficking. (C) 2021 The Authors. Published by Elsevier GmbH.
引用
收藏
页数:11
相关论文
共 35 条
  • [1] Downregulation of a GPCR by β-Arrestin2-Mediated Switch from an Endosomal to a TGN Recycling Pathway
    Abdullah, Nazish
    Beg, Muheeb
    Soares, David
    Dittman, Jeremy S.
    McGraw, Timothy E.
    [J]. CELL REPORTS, 2016, 17 (11): : 2966 - 2978
  • [2] [Anonymous], J CLIN INVEST, V91
  • [3] Chronic exposure to GLP-IR agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo
    Baggio, LL
    Kim, JG
    Drucker, DJ
    [J]. DIABETES, 2004, 53 : S205 - S214
  • [4] Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
    Bettge, Karolin
    Kahle, Melanie
    Abd El Aziz, Mirna S.
    Meier, Juris J.
    Nauck, Michael A.
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (03) : 336 - 347
  • [5] LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
    Coskun, Tamer
    Sloop, Kyle W.
    Loghin, Corina
    Alsina-Fernandez, Jorge
    Urva, Shweta
    Bokvist, Krister B.
    Cui, Xuewei
    Briere, Daniel A.
    Cabrera, Over
    Roell, William C.
    Kuchibhotla, Uma
    Moyers, Julie S.
    Benson, Charles T.
    Gimeno, Ruth E.
    D'Alessio, David A.
    Haupt, Axel
    [J]. MOLECULAR METABOLISM, 2018, 18 : 3 - 14
  • [6] CD26, let it cut or cut it down
    De Meester, I
    Korom, S
    Van Damme, J
    Scharpé, S
    [J]. IMMUNOLOGY TODAY, 1999, 20 (08): : 367 - 375
  • [7] DEACON CF, 1995, J CLIN ENDOCR METAB, V80, P952, DOI 10.1210/jcem.80.3.7883856
  • [8] Asymmetric Recruitment of β-Arrestin1/2 by the Angiotensin II Type I and Prostaglandin F2α Receptor Dimer
    Fillion, Dany
    Devost, Dominic
    Steno, Rory
    Inoue, Asuka
    Hebert, Terence E.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [9] Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
    Finan, Brian
    Ma, Tao
    Ottaway, Nickki
    Mueller, Timo D.
    Habegger, Kirk M.
    Heppner, Kristy M.
    Kirchner, Henriette
    Holland, Jenna
    Hembree, Jazzminn
    Raver, Christine
    Lockie, Sarah H.
    Smiley, David L.
    Gelfanov, Vasily
    Yang, Bin
    Hofmann, Susanna
    Bruemmer, Dennis
    Drucker, Daniel J.
    Pfluger, Paul T.
    Perez-Tilve, Diego
    Gidda, Jaswant
    Vignati, Louis
    Zhang, Lianshan
    Hauptman, Jonathan B.
    Lau, Michele
    Brecheisen, Mathieu
    Uhles, Sabine
    Riboulet, William
    Hainaut, Emmanuelle
    Sebokova, Elena
    Conde-Knape, Karin
    Konkar, Anish
    DiMarchi, Richard D.
    Tschoep, Matthias H.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (209)
  • [10] Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
    Frias, Juan Pablo
    Nauck, Michael A.
    Van, Joanna
    Kutner, Mark E.
    Cui, Xuewei
    Benson, Charles
    Urva, Shweta
    Gimeno, Ruth E.
    Milicevic, Zvonko
    Robins, Deborah
    Haupt, Axel
    [J]. LANCET, 2018, 392 (10160) : 2180 - 2193